These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31597003)

  • 1. Update on the guideline of guidelines: non-muscle-invasive bladder cancer.
    Taylor J; Becher E; Steinberg GD
    BJU Int; 2020 Feb; 125(2):197-205. PubMed ID: 31597003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
    Kramer MW; Gakis G
    Urologe A; 2020 Jul; 59(7):784-789. PubMed ID: 32468091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
    Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
    Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-muscle invasive bladder cancer].
    Irani J
    Rev Prat; 2014 Dec; 64(10):1382-5. PubMed ID: 25665317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling non-muscle invasive bladder cancer in the clinic.
    Woldu SL; Şanli Ö; Lotan Y
    Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
    Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
    Abufaraj M; Mostafid H; Shariat SF; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.